MX2018004545A - Anticuerpos anti-age y metodos para utilizarlos. - Google Patents
Anticuerpos anti-age y metodos para utilizarlos.Info
- Publication number
- MX2018004545A MX2018004545A MX2018004545A MX2018004545A MX2018004545A MX 2018004545 A MX2018004545 A MX 2018004545A MX 2018004545 A MX2018004545 A MX 2018004545A MX 2018004545 A MX2018004545 A MX 2018004545A MX 2018004545 A MX2018004545 A MX 2018004545A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- delaying
- onset
- preventing
- sequence identity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562241007P | 2015-10-13 | 2015-10-13 | |
US14/974,561 US10358502B2 (en) | 2014-12-18 | 2015-12-18 | Product and method for treating sarcopenia |
PCT/US2016/034880 WO2017065837A1 (en) | 2015-10-13 | 2016-05-27 | Anti-age antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018004545A true MX2018004545A (es) | 2018-08-01 |
Family
ID=58518256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004545A MX2018004545A (es) | 2015-10-13 | 2016-05-27 | Anticuerpos anti-age y metodos para utilizarlos. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3362483A1 (ru) |
JP (1) | JP2018535953A (ru) |
KR (1) | KR20180056689A (ru) |
CN (1) | CN108431044A (ru) |
AU (1) | AU2016336959A1 (ru) |
BR (1) | BR112018007422A2 (ru) |
CA (1) | CA3000815C (ru) |
IL (1) | IL258397A (ru) |
MA (1) | MA42979A (ru) |
MX (1) | MX2018004545A (ru) |
RU (1) | RU2766209C2 (ru) |
WO (1) | WO2017065837A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120127543A (ko) | 2008-05-23 | 2012-11-21 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
WO2012047629A2 (en) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of ather0sclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
BR112017005517A2 (pt) | 2014-09-19 | 2017-12-05 | Siwa Corp | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
EP3677598B1 (en) * | 2016-02-19 | 2022-04-06 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
CN109311975A (zh) | 2016-04-15 | 2019-02-05 | Siwa有限公司 | 用于治疗神经退行性紊乱的抗age抗体 |
JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
EP3609923A1 (en) * | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
EP3619540A1 (en) * | 2017-05-04 | 2020-03-11 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
JP6994876B2 (ja) * | 2017-09-05 | 2022-01-14 | 株式会社エッグ | 計測器 |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
WO2019183282A1 (en) * | 2018-03-21 | 2019-09-26 | Mayo Foundation For Medical Education And Research | Senolytic agents for the treatment of tauopathies |
JP2021532114A (ja) * | 2018-07-23 | 2021-11-25 | シワ コーポレーション | 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 |
JP2021534144A (ja) * | 2018-08-23 | 2021-12-09 | シワ コーポレーション | Age修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波 |
CN117642431A (zh) * | 2021-07-13 | 2024-03-01 | 迈威(美国)生物治疗有限公司 | 抗c1s抗体和其用途 |
CN114031687B (zh) * | 2021-11-12 | 2022-06-07 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
WO2023177390A1 (en) * | 2022-03-14 | 2023-09-21 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
DE10084743T1 (de) * | 1999-06-25 | 2002-08-14 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern |
JP4012722B2 (ja) * | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
US20100226932A1 (en) | 2006-02-22 | 2010-09-09 | Novavax, Inc. | Adjuvant and Vaccine Compositions |
KR20120127543A (ko) | 2008-05-23 | 2012-11-21 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
-
2016
- 2016-05-27 KR KR1020187010762A patent/KR20180056689A/ko not_active Application Discontinuation
- 2016-05-27 AU AU2016336959A patent/AU2016336959A1/en not_active Abandoned
- 2016-05-27 EP EP16731696.7A patent/EP3362483A1/en not_active Withdrawn
- 2016-05-27 MX MX2018004545A patent/MX2018004545A/es unknown
- 2016-05-27 WO PCT/US2016/034880 patent/WO2017065837A1/en active Application Filing
- 2016-05-27 CN CN201680059997.5A patent/CN108431044A/zh active Pending
- 2016-05-27 RU RU2018110885A patent/RU2766209C2/ru active
- 2016-05-27 BR BR112018007422A patent/BR112018007422A2/pt not_active Application Discontinuation
- 2016-05-27 MA MA042979A patent/MA42979A/fr unknown
- 2016-05-27 CA CA3000815A patent/CA3000815C/en active Active
- 2016-05-27 JP JP2018519727A patent/JP2018535953A/ja active Pending
-
2018
- 2018-03-27 IL IL258397A patent/IL258397A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
Also Published As
Publication number | Publication date |
---|---|
BR112018007422A2 (pt) | 2018-10-30 |
AU2016336959A1 (en) | 2018-04-12 |
RU2018110885A3 (ru) | 2020-01-30 |
MA42979A (fr) | 2021-05-26 |
JP2018535953A (ja) | 2018-12-06 |
KR20180056689A (ko) | 2018-05-29 |
IL258397A (en) | 2018-05-31 |
RU2766209C2 (ru) | 2022-02-09 |
WO2017065837A1 (en) | 2017-04-20 |
EP3362483A1 (en) | 2018-08-22 |
CA3000815A1 (en) | 2017-04-20 |
CA3000815C (en) | 2022-11-01 |
RU2018110885A (ru) | 2019-11-19 |
CN108431044A (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018004545A (es) | Anticuerpos anti-age y metodos para utilizarlos. | |
MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
MX2018001387A (es) | Anticuerpo de dominio simple y proteinas derivadas del mismo contra ligando de muerte programada (pdl1). | |
MX2023001403A (es) | Neoantigenos y metodos de su uso. | |
EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
CY1125102T1 (el) | Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης | |
MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
BR112016000654A2 (pt) | composições para a modulação de expressão de tau | |
MX2018011035A (es) | Anticuerpos-anti-mica. | |
PH12018501025A1 (en) | Improved tnf binders | |
BR112014018592A2 (pt) | composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos | |
PH12014501604A1 (en) | Polypeptides binding to human complement c5 | |
EA201690898A1 (ru) | Способы лечения таупатии | |
EP3936141A3 (en) | Anti-senescence compounds and uses thereof | |
MX2023008211A (es) | Composiciones y metodos para disminuir la expresion de tau. | |
EA201491277A1 (ru) | Противораковый слитый белок | |
EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
MX2019005693A (es) | Factor viii direccionado a los globulos rojos y metodo para su uso. | |
WO2018138032A3 (en) | NKp46 BINDING AGENTS | |
EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
EA202090513A1 (ru) | Агенты, модулирующие функции бета-катенина, и связанные способы |